Amendment to Annual Report (Form 10-K/A)

Immix Biopharma, Inc. (the "Company") is filing this Amendment No. 1 on Form 10-K/A (this "Amendment") to amend its Annual Report on Form 10-K for the year ended December 31, 2025, previously filed with the Securities and Exchange Commission (the "SEC") on March 25, 2026 (the "Original Filing"), for the sole purpose of reflecting the correct date of the Report of Independent Registered Public Accounting Firm (the "Auditor Report") (correct: March 25, 2026). No other changes have been made to the financial reports or 10-K content compared to the 10-K filed on March 25, 2026.

In addition, pursuant to the rules of the SEC, the exhibit list included herewith reflects currently-dated auditor consent and certifications from the Company's Chief Executive Officer and Chief Financial Officer, which are filed as exhibits to this Amendment No. 1.

Except for the foregoing amended information, this Amendment No. 1 does not amend or update any other information contained in the Original Filing, or reflect any events that have occurred after the filing of the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing.